-
Fennec reports positive Japan trial results for PEDMARK hearing loss drug
-
Fennec Pharmaceuticals completes full debt redemption
-
Fennec Pharmaceuticals (FENC) Misses Q3 EPS by 9c
-
Fennec Pharmaceuticals Inc. (FENC) PT Raised to $14 at Craig-Hallum
-
Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 7c
-
Fennec Pharmaceuticals (FENC) announces voting results from AGM
-
Fennec Pharmaceuticals (FENC) Tops Q1 EPS by 6c
-
H.C. Wainwright Reiterates Buy Rating on Fennec Pharmaceuticals Inc. (FENC)
-
Fennec Pharmaceuticals (FENC) Tops Q4 EPS by 7c
-
Fennec Pharmaceuticals (FENC) Announces Commercial Launch of PEDMARQSI In Germany
-
Fennec Pharmaceuticals (FENC) Reports Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
-
Fennec Pharmaceuticals (FENC) Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
-
Fennec Pharmaceuticals (FENC) Misses Q3 EPS by 11c
-
Fennec Pharmaceuticals Inc. (FENC) PT Lowered to $13 at H.C. Wainwright
-
Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 18c
-
Jeffrey S. Hackman Appointed as CEO and Director at Fennec Pharmaceuticals (FENC)
-
Fennec Pharmaceuticals (FENC) Announces Management Change

